|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Total blood volume (TBV) was measured clinically using a radiolabeled albumin indicator-dilution technique in patients with predominately class III ambulatory chronic HF (N=66).
|
31568830 |
2020 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Early changes after randomization in levels of 3 biomarkers (urinary albumin:creatinine ratio, serum bicarbonate, and serum urate) were identified as mediating the effect of canagliflozin on heart failure.
|
31676303 |
2020 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum albumin (Alb) is reported as a useful risk-stratification tool in cardiovascular diseases such as acute coronary syndrome or heart failure.
|
31269058 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study examined the association between urinary albumin excretion and incident heart failure (HF) hospitalization.
|
31047019 |
2019 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using non-linear models with machine learning software, 118 risk factors and their weighting of risk for all-cause mortality, heart failure (HF), acute coronary syndrome (ACS), ischemic stroke (IS), and intracranial hemorrhage (ICH) were identified, where the top two risk factors were albumin/hemoglobin, left ventricular ejection fraction/history of HF, history of ACS/anti-platelet use, history of IS/deceleration time, and history of ICH/warfarin use.
|
31499517 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Associated factors of HRV included advanced CKD, diabetes mellitus, serum albumin, severe proteinuria, Beck Anxiety Inventory score, erythropoietin use, renin-angiotensin system inhibitors and heart failure.
|
30328166 |
2019 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Objective:</b> The prognostic utility of serum albumin level for mortality in heart failure patients has received considerable attention.
|
31379211 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Functionally, in vivo glycated albumin in patients with HF induced an increase in adhesion molecules expression on HUVEC, which supported an increase in peripheral blood mononuclear cells adhesion to endothelial cells.
|
30875658 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptor agonist treatment reduced all-cause mortality by 12% (0·88, 0·83-0·95; p=0·001), hospital admission for heart failure by 9% (0·91, 0·83-0·99; p=0·028), and a broad composite kidney outcome (development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate [or increase in creatinine], progression to end-stage kidney disease, or death attributable to kidney causes) by 17% (0·83, 0·78-0·89; p<0·0001), mainly due to a reduction in urinary albumin excretion.
|
31422062 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum and Urine Albumin and Response to Loop Diuretics in Heart Failure.
|
31010938 |
2019 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lower concentrations of serum albumin appear to be associated with an increased risk of all-cause and cardiovascular mortality, coronary heart disease, heart failure and stroke.
|
29573083 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
After the treatment, the body mass index, skinfold thickness of upper arm triceps, muscle circumference of the upper arm, upper arm muscle circumference, total protein, albumin, hemoglobin, and left ventricular ejection fraction in the treatment groups all increased, with relatively obvious relief of symptoms of heart failure.
|
29563779 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effect of Oral Branched-Chain Amino Acids on Serum Albumin Concentration in Heart Failure Patients with Hypoalbuminemia: Results of a Preliminary Study.
|
29511994 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum levels of ALB and GLB are objective and easily measurable biomarkers which can be used in combination to predict the survival of patients with HF.
|
29982222 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of levocarnitine on cardiac function, urinary albumin, hs-CRP, BNP, and troponin in patients with coronary heart disease and heart failure.
|
30195728 |
2018 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prognostic Implications of Changes in Albumin Following Left Ventricular Assist Device Implantation in Patients With Severe Heart Failure.
|
28947307 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our aim was to study short-term changes in serum albumin, total protein and body weight following LVAD implantation and to compare these changes with heart failure patients treated medically.
|
27939745 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated associations of high TNFR1 with baseline estimated glomerular filtration rate (eGFR) and urine albumin to creatinine ratio (ACR) and with longitudinal changes in eGFR (rapid loss), as well as with incident myocardial infarction (MI), heart failure hospitalizations (HF), and mortality over a median follow-up time of 8.9 years.
|
28601698 |
2017 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, albumin level ≤3.50 g/dl is an independent predictor of new-onset heart failure and in-hospital mortality in patients with ACS.
|
28160977 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined the association between albumin and hospital mortality in a cohort of 546 patients admitted for acute non-ischemic HF.
|
28451450 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Proteomic analyses of blood samples were performed by 2-D-DiGE after plasma depletion of albumin and immunoglobulins G. New York Heart Association (NYHA) class determined at 1-year follow-up was used to identify patients with heart failure.
|
21767674 |
2011 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
CTD_human |
Human serum albumin induced hypotension in the postoperative phase of cardiac surgery.
|
11771600 |
2001 |